Liquidia (NASDAQ:LQDA) CFO Michael Kaseta Sells 133,789 Shares

Key Points

• CFO Michael Kaseta sold 133,789 shares on April 9 at an average price of $40.24 (≈$5.38M) under a pre‑arranged Rule 10b5‑1 plan, cutting his stake by 24.52% to 411,855 shares valued at about $16.57M.
• Liquidia beat the quarter with EPS of $0.15 versus $0.08 expected and revenue of $92.02M (up 3,072% YoY), but still shows negative ROE and net margin; analysts have an average rating of "Moderate Buy" with a $43.44 price target and several firms raising targets to $50–$55.
• The stock traded at $38.85 (up 0.8%), has a 52‑week range of $11.85–$46.67 and a market cap around $3.42B, with institutional investors owning roughly 64.5% of shares.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CFO Michael Kaseta sold 133,789 shares of the firm's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $40.24, for a total value of $5,383,669.36. Following the sale, the chief financial officer owned 411,855 shares of the company's stock, valued at $16,573,045.20. The trade was a 24.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Liquidia Stock Up 0.8%

NASDAQ LQDA traded up $0.30 during trading on Monday, reaching $38.85. 700,362 shares of the company's stock were exchanged, compared to its average volume of 1,789,002. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $46.67. The firm has a market capitalization of $3.42 billion, a PE ratio of -46.81 and a beta of 0.45. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97. The company's fifty day simple moving average is $36.98 and its 200-day simple moving average is $32.80.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The firm had revenue of $92.02 million during the quarter, compared to analyst estimates of $87.49 million. The firm's revenue was up 3072.4% compared to the same quarter last year. Sell-side analysts predict that Liquidia Corporation will post -1.51 EPS for the current year.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia in the 4th quarter worth approximately $25,000. Covestor Ltd lifted its holdings in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock worth $42,000 after purchasing an additional 359 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in Liquidia in the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC acquired a new stake in Liquidia in the 3rd quarter worth approximately $34,000. Finally, NewEdge Advisors LLC acquired a new stake in Liquidia in the 2nd quarter worth approximately $25,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Jefferies Financial Group upped their price objective on shares of Liquidia from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, January 13th. Zacks Research downgraded Liquidia from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 27th. BTIG Research raised their price objective on Liquidia from $49.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Liquidia in a report on Thursday, January 22nd. Finally, HC Wainwright boosted their target price on Liquidia from $50.00 to $55.00 and gave the stock a "buy" rating in a report on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $43.44.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.